Interview: Sandoz CEO On Biosimilars And Reshaping US Business
Executive Summary
Observers were left surprised by the size of the decline in US sales at Sandoz during the fourth quarter. Richard Francis, CEO of Novartis' generics division, told Scrip about plans to turn the business around in which biosimilars will figure largely.
You may also be interested in...
Novartis Blows Storm Clouds Off Sandoz US In Aurobindo Sale
Novartis's proposed sale of its generic oral solids portfolio – which has been battered by US price erosion – and the Sandoz US dermatology business to Aurobindo Pharma, in a deal potentially worth $1bn, allows the unit to finally concentrate on biosimilars, value-added medicines and complex generics.
Novartis Blows Storm Clouds Off Sandoz US In Aurobindo Sale
Novartis's proposed sale of its generic oral solids portfolio – which has been battered by US price erosion – and the Sandoz US dermatology business to Aurobindo Pharma, in a deal potentially worth $1bn, allows the unit to finally concentrate on biosimilars, value-added medicines and complex generics.
Novartis Sees The Light And Plumps For Alcon Spin-Off
Having acquired Alcon for an eye-watering $52bn seven years ago, the Swiss major has decided that spinning off the eyecare business which has finally returned to growth (but is worth about half what Novartis paid in 2011) makes the most sense as it becomes a company even more focused on pharma.